DOD Reconstructive Transplant, Investigator-Initiated Research Award | HT9425 23 RTRP IIRA

Opportunity Information: Apply for HT9425 23 RTRP IIRA

The FY23 Department of Defense Reconstructive Transplant Research Program (RTRP) Investigator-Initiated Research Award (IIRA) is a competitive funding opportunity designed to move the science of reconstructive transplantation forward in ways that can meaningfully improve patient care and long-term quality of life. It supports investigator-driven, potentially high-impact ideas, but it is not a blank-check for speculative concepts; proposals are expected to be grounded in a strong scientific rationale and framed around practical usefulness for military-connected populations. The awarding component is the Department of Defense, Department of the Army, U.S. Army Medical Research Acquisition Activity (USAMRAA), and the opportunity is listed under Funding Opportunity Number HT9425 23 RTRP IIRA.

At its core, the award is meant to fund research that strengthens the evidence base and biological understanding behind reconstructive transplant approaches, including vascularized composite allotransplantation (VCA), such as face, hand, or other complex tissue transplants. The program explicitly looks for studies that can contribute to the field in both near-term and longer-term horizons, whether that impact comes through better graft outcomes, improved functional recovery, reduced complications, improved immunologic management, or other patient-centered gains that ultimately translate into better lives for recipients and their families.

A major theme of the announcement is rigor and feasibility. Applicants are expected to present a clearly described study design that can stand up to scrutiny and that is built for reproducibility and translation. In practical terms, that means reviewers will be looking for methods that are appropriately controlled, well justified, and realistic for the resources and timeline proposed. Where statistical analysis is applicable, the application should include a statistical plan and an appropriate power analysis, signaling that the study is sized and structured to answer its central questions rather than simply generate exploratory signals.

Impact is another central review lens. The application needs to spell out what success would change, both immediately and down the road, and it must align with at least one of the FY23 RTRP Investigator-Initiated Research Award Focus Areas (the specific focus areas are referenced as a requirement even though they are not listed in the text provided). In other words, a proposal should not only be scientifically interesting; it should map cleanly to program priorities and make a convincing case that the results could shift the field, influence clinical thinking, or unlock a clearer path toward better outcomes in reconstructive transplantation.

Military relevance is required. The proposed work must be responsive to the health care needs of Service Members and/or Veterans recovering from traumatic injury, and it may also address the needs of their family members, caregivers, and clinicians, while still benefiting the general public. Collaboration with military researchers or clinicians is encouraged as a way to strengthen relevance and access to expertise, but it is not mandatory. Even without a formal military partner, applicants are expected to make the military utility clear, particularly in the context of trauma-related reconstruction challenges and the real-world constraints of caring for injured warfighters and Veterans.

The program also places emphasis on preliminary support for the concept. The announcement recognizes that strong ideas can originate from many sources, including laboratory discoveries, population-based findings, clinician experience at the bedside, or even well-founded anecdotal observations. Still, the application must include preliminary and/or published data that are directly relevant to reconstructive transplantation and that credibly support the proposed rationale. The point is to ensure that the project is anchored in evidence that makes the hypotheses and approach believable and testable.

An important flexibility built into the announcement is the ability to leverage advances from solid organ transplantation research and bring them into a VCA context, as long as the applicant clearly explains why the translation is justified. Reviewers will expect a reasoned argument for why the result might differ in VCA, why it matters to confirm whether the result holds true in VCA, or how repeating or adapting the work in a VCA setting could reveal new mechanisms or clarify features unique to composite tissue transplantation. This is essentially an invitation to import strong ideas from adjacent transplant domains, but with the expectation that applicants understand and can articulate what makes VCA distinct.

In terms of research scope, the IIRA supports a broad spectrum from basic science through translational research. That can include preclinical studies in animal models, studies involving human subjects (so long as they do not meet the definition of a clinical trial), research using human anatomical substances, and correlative studies that are tied to an existing clinical trial. The key restriction is that new clinical trials are not allowed. The opportunity uses a standard definition of a clinical trial: any study in which human subjects are prospectively assigned to one or more interventions (including placebo or control) to evaluate effects on biomedical or behavioral health outcomes. This means applicants can often still do meaningful human-centered work (for example, observational, correlative, or mechanistic studies) as long as they are not prospectively assigning interventions to test outcomes.

Administratively, the funding instrument can be either a grant or a cooperative agreement. Eligibility is described as unrestricted, meaning the opportunity is broadly open to many entity types, subject to any additional clarifications in the full announcement. The CFDA number is 12.420, and the activity category is Science and Technology and other Research and Development. The opportunity was created June 5, 2023, with an original closing date of October 11, 2023. The posting anticipated approximately three awards. The listed award ceiling is shown as 0, which typically indicates that applicants need to rely on the full announcement for budget limits or that ceiling information is handled elsewhere in the solicitation documents rather than in the summary field.

Overall, the DoD RTRP Investigator-Initiated Research Award is structured for researchers with compelling, well-supported ideas in reconstructive transplantation who can demonstrate methodological rigor, meaningful impact aligned to program focus areas, and clear relevance to the recovery needs of injured Service Members and Veterans. It encourages ambitious science, but it insists on careful design, credible preliminary grounding, and a realistic path toward translation without funding new clinical trials.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DOD Reconstructive Transplant, Investigator-Initiated Research Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Jun 05, 2023.
• Applicants must submit their applications by Oct 11, 2023. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 3 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for HT9425 23 RTRP IIRA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: